Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Everett E. Vokes

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Vokes, Everett E.

Item TypeName
Concept Proto-Oncogene Proteins c-met
Academic Article PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
Academic Article MET as a target for treatment of chest tumors.
Academic Article The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Academic Article Expression and mutational analysis of MET in human solid cancers.
Academic Article Ethnic differences and functional analysis of MET mutations in lung cancer.
Academic Article CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Academic Article MET and phosphorylated MET as potential biomarkers in lung cancer.
Academic Article Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
Academic Article Personalized treatment of lung cancer.
Academic Article RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Academic Article Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Academic Article Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
Academic Article Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Academic Article Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Academic Article Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
Academic Article Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.

Search Criteria
  • Proto Oncogene Proteins c met